医学
银屑病
皮肤病科
荟萃分析
钉子(扣件)
梅德林
指甲病
内科学
政治学
冶金
材料科学
法学
作者
I‐Hsin Huang,Po‐Chien Wu,Ting‐Hua Yang,Hua Li,Yuting Huang,Ying‐Chih Cheng,Po-Hsiu Kuo,Ya‐Han Lee,Yu‐Chen Huang,Yu‐Kang Tu
标识
DOI:10.1016/j.jaad.2021.01.024
摘要
Background
Various systemic immunomodulating therapies have been investigated to treat nail psoriasis, but the efficacy remains unclear. Objective
To perform a systematic review and network meta-analysis to evaluate the efficacy of small molecule inhibitors and biologics in treating nail psoriasis. Methods
Eligible studies in online databases were identified until March 10, 2020. To assess the efficacy of small molecule inhibitors and biologics, network meta-analyses with surface under the cumulative ranking curve of improvement in nail score at 10 to 16 and at 24 to 26 weeks, as well as 100% improvement of Nail Psoriasis Severity Index (NAPSI), were performed. Results
Thirty-nine studies with a total of 13 treatment arms involving 15,673 patients with nail psoriasis were included. An network meta-analysis showed that tofacitinib (weighted mean difference, 56.67; 95% confidence interval [CI], 35.87-77.48) and ixekizumab (weighted mean difference, 59.40; 95% CI, 45.87-72.93) presented the most improvement of nail score at 10 to 16 weeks and 24 to 26 weeks, respectively. For 100% improvement of the Nail Psoriasis Severity Index, ixekizumab showed the best efficacy among all treatments (odds ratio, 2.98; 95% CI, 1.74-5.10). Limitations
Insufficiency of eligible data and no long-term follow-up data. Conclusion
Tofacitinib and ixekizumab presented the best efficacy for treating nail psoriasis in 10 to 16 weeks and 24 to 26 weeks, respectively.
科研通智能强力驱动
Strongly Powered by AbleSci AI